FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2002253478> ?p ?o ?g. }

• W2002253478 endingPage "392" @default.
• W2002253478 startingPage "382" @default.
• W2002253478 abstract "Chronic levodopa treatment in patients with Parkinson's disease frequently results in the development of motor complications, including dyskinesias and motor fluctuations. This review presents evidence that these complications are associated with discontinuous stimulation of dopamine receptors that is induced by intermittent oral doses of levodopa, and the authors propose alternative therapeutic approaches based on the principle of continuous dopaminergic stimulation. Continuous dopaminergic stimulation is a therapeutic strategy for the management of Parkinson's disease, which proposes that dopaminergic agents that provide continuous stimulation of striatal dopamine receptors will delay or prevent the onset of levodopa-related motor complications. Dopaminergic neurons in the basal ganglia normally fire in a random but continuous manner, so that striatal dopamine concentrations are maintained at a relatively constant level. In the dopamine-depleted state, however, intermittent oral doses of levodopa induce discontinuous stimulation of striatal dopamine receptors. This pulsatile stimulation leads to molecular and physiologic changes in basal ganglia neurons and the development of motor complications. These effects are reduced or avoided when dopaminergic therapies are delivered in a more continuous and physiologic manner. Studies in primate models and patients with Parkinson's disease have shown that continuous or long-acting dopaminergic agents are associated with a decreased risk of motor complications compared with short-acting dopamine agonists or levodopa formulations. Continuous dopaminergic stimulation can be achieved with a continuous infusion, but infusion therapies are cumbersome and not likely to be acceptable to patients with early disease. The current challenge is to develop a long-acting oral formulation of levodopa that provides comparable anti-parkinsonian benefits without motor complications." @default.
• W2002253478 created "2016-06-24" @default.
• W2002253478 creator A5031345514 @default.
• W2002253478 creator A5062838955 @default.
• W2002253478 creator A5088654646 @default.
• W2002253478 date "2006-07-01" @default.
• W2002253478 modified "2023-10-18" @default.
• W2002253478 title "Drug Insight: continuous dopaminergic stimulation in the treatment of Parkinson's disease" @default.
• W2002253478 cites W1533056363 @default.
• W2002253478 cites W1571781207 @default.
• W2002253478 cites W1633847368 @default.
• W2002253478 cites W1783167873 @default.
• W2002253478 cites W1832682301 @default.
• W2002253478 cites W1966443363 @default.
• W2002253478 cites W1982827121 @default.
• W2002253478 cites W1985133850 @default.
• W2002253478 cites W1989605251 @default.
• W2002253478 cites W1991532308 @default.
• W2002253478 cites W1995563033 @default.
• W2002253478 cites W1997887984 @default.
• W2002253478 cites W1998896287 @default.
• W2002253478 cites W1999984492 @default.
• W2002253478 cites W2000914933 @default.
• W2002253478 cites W2010206955 @default.
• W2002253478 cites W2015594730 @default.
• W2002253478 cites W2017055459 @default.
• W2002253478 cites W2023062380 @default.
• W2002253478 cites W2026246620 @default.
• W2002253478 cites W2028193214 @default.
• W2002253478 cites W2034770217 @default.
• W2002253478 cites W2034825135 @default.
• W2002253478 cites W2035286056 @default.
• W2002253478 cites W2040639040 @default.
• W2002253478 cites W2041694263 @default.
• W2002253478 cites W2048051000 @default.
• W2002253478 cites W2054821578 @default.
• W2002253478 cites W2058423830 @default.
• W2002253478 cites W2060588252 @default.
• W2002253478 cites W2061460058 @default.
• W2002253478 cites W2062524799 @default.
• W2002253478 cites W2066217835 @default.
• W2002253478 cites W2069312167 @default.
• W2002253478 cites W2071948878 @default.
• W2002253478 cites W2072788041 @default.
• W2002253478 cites W2073630554 @default.
• W2002253478 cites W2076281963 @default.
• W2002253478 cites W2082051942 @default.
• W2002253478 cites W2085965461 @default.
• W2002253478 cites W2090089396 @default.
• W2002253478 cites W2091110931 @default.
• W2002253478 cites W2092634694 @default.
• W2002253478 cites W2092980697 @default.
• W2002253478 cites W2095111193 @default.
• W2002253478 cites W2103964804 @default.
• W2002253478 cites W2106158259 @default.
• W2002253478 cites W2109059823 @default.
• W2002253478 cites W2111505835 @default.
• W2002253478 cites W2112615200 @default.
• W2002253478 cites W2114122417 @default.
• W2002253478 cites W2123240188 @default.
• W2002253478 cites W2126621555 @default.
• W2002253478 cites W2126680030 @default.
• W2002253478 cites W2130696280 @default.
• W2002253478 cites W2143807044 @default.
• W2002253478 cites W2145473326 @default.
• W2002253478 cites W2146662310 @default.
• W2002253478 cites W2149402023 @default.
• W2002253478 cites W2149958198 @default.
• W2002253478 cites W2156629529 @default.
• W2002253478 cites W2158620349 @default.
• W2002253478 cites W2165152810 @default.
• W2002253478 cites W2166534380 @default.
• W2002253478 cites W2167227624 @default.
• W2002253478 cites W2186321983 @default.
• W2002253478 cites W2238469074 @default.
• W2002253478 cites W2322912881 @default.
• W2002253478 cites W2430879907 @default.
• W2002253478 cites W243899736 @default.
• W2002253478 cites W2945812229 @default.
• W2002253478 cites W3027974929 @default.
• W2002253478 cites W37005 @default.
• W2002253478 cites W4206634583 @default.
• W2002253478 cites W4250151684 @default.
• W2002253478 cites W4252472226 @default.
• W2002253478 cites W4253345114 @default.
• W2002253478 cites W4255433669 @default.
• W2002253478 cites W4317929355 @default.
• W2002253478 doi "https://doi.org/10.1038/ncpneuro0222" @default.
• W2002253478 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16932589" @default.
• W2002253478 hasPublicationYear "2006" @default.
• W2002253478 type Work @default.
• W2002253478 sameAs 2002253478 @default.
• W2002253478 citedByCount "118" @default.
• W2002253478 countsByYear W20022534782012 @default.
• W2002253478 countsByYear W20022534782013 @default.
• W2002253478 countsByYear W20022534782014 @default.
• W2002253478 countsByYear W20022534782015 @default.
• W2002253478 countsByYear W20022534782016 @default.

• next